Loading
Dialysis and Renal Disease Management · Journal article
Scientific Reports · September 7, 2026
Raises a question worth testing. It does not answer one.
This preclinical study in mice links high dietary tyrosine to increased gut microbial phenol production and associates this with reduced energy expenditure, increased adiposity, and skeletal muscle atrophy, reversible partly by a phenol-lyase inhibitor. The work is mechanistic and exploratory; it does not establish causation in humans or define clinical significance.
Preclinical experimental study in mice with dietary intervention and pharmacological antagonism. Laboratory mice; specific strain, age, sex, and group size not stated in abstract.. Intervention: High-tyrosine diet and 3,5-dihydroxybenzoic acid (35DHBA) administration.. Compared with: Standard diet (control); phenol-lyase inhibition versus untreated phenol elevation..
High-tyrosine feeding markedly increased fecal phenol and circulating phenyl sulfate (PhS) levels without affecting body weight, food intake, or glucose tolerance. Respiratory gas analysis revealed reduced energy expenditure and carbohydrate oxidation during the dark phase in the tyrosine-fed group. CT and histological analyses demonstrated increased adiposity, adipocyte hypertrophy, and reduced skeletal muscle fiber size in the tyrosine-fed group.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical work suggests a novel mechanism linking dietary amino acid composition to microbial metabolite–driven metabolic dysfunction. Findings cannot yet guide clinical practice and require validation in human populations and disease models before translational application is considered.
A mechanistic, preclinical mouse study raising a question about phenol's role in metabolism and body composition; findings need confirmation in humans and disease models.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical work suggests a novel mechanism linking dietary amino acid composition to microbial metabolite–driven metabolic dysfunction. Findings cannot yet guide clinical practice and require validation in human populations and disease models before translational application is considered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Gut microbial phenol has been recognized as a uremic toxin associated with chronic kidney disease; however, its effects under preclinical conditions remain unclear. In this study, we established a mouse model with increased endogenous phenol production using a tyrosine-rich diet. High-tyrosine feeding markedly increased fecal phenol and circulating phenyl sulfate (PhS) levels without affecting body weight, food intake, or glucose tolerance. In contrast, respiratory gas analysis revealed reduced energy expenditure and carbohydrate oxidation during the dark phase. CT and histological analyses demonstrated increased adiposity, adipocyte hypertrophy, and reduced skeletal muscle fiber size in the tyrosine-fed group. Inflammatory cytokines in adipose tissue and liver were also elevated. These alterations were largely suppressed by administration of the tyrosine phenol-lyase inhibitor 3,5-dihydroxybenzoic acid (35DHBA), accompanied by a marked reduction in phenol production. Although plasma PhS levels were elevated, no apparent renal dysfunction was observed in the current experimental conditions. These results suggest that gut microbial phenol production may contribute to alterations in energy metabolism and body composition before the onset of overt kidney dysfunction. Our findings indicate that microbial phenol production is potentially involved in metabolic abnormalities associated with excess dietary tyrosine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.